Wedbush raised the firm’s price target on Rezolute (RZLT) to $2 from $1 and keeps a Neutral rating on the shares. The firm notes the company reported PK/PD data and detailed glycemic control outcomes from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism. Wedbush believes that the new data demonstrates ersodetug’s activity in modulating insulin receptors to reduce both events and time in hypoglycemia in treated patients, although whether the magnitude of benefit is sufficient to support an FDA approval remains unclear.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
- Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
- Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
- Rezolute shares findings from Expanded Access Program in tumor HI
- Rezolute shares observations from Phase 3 sunRIZE study in congenital HI